Patents by Inventor Omar L. Francone

Omar L. Francone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating phenylketonuria
    Patent number: 11952585
    Abstract: Provided herein are methods of treating a subject having a disease or disorder associated with a PAH gene mutation. The methods generally comprise administering to the subject a therapeutically effective does of a recombinant adeno-associated virus (rAAV) that can express a phenylalanine hydroxylase (PAH) polypeptide in a cell and thereby restore PAH gene function in the subject.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: April 9, 2024
    Assignee: HOMOLOGY MEDICINES, INC.
    Inventors: Omar L. Francone, Deborah A. Kinch, Diana Lamppu, Albert Barnes Seymour, Teresa Leah Wright
  • METHODS OF TREATING PHENYLKETONURIA
    Publication number: 20210261983
    Abstract: Provided herein are methods of treating a subject having a disease or disorder associated with a PAH gene mutation. The methods generally comprise administering to the subject a therapeutically effective does of a recombinant adeno-associated virus (rAAV) that can express a phenylalanine hydroxylase (PAH) polypeptide in a cell and thereby restore PAH gene function in the subject.
    Type: Application
    Filed: January 13, 2021
    Publication date: August 26, 2021
    Inventors: Omar L. Francone, Deborah A. Kinch, Diana Lamppu, Albert Barnes Seymour, Teresa Leah Wright
  • LIPOPROTEIN LIPASE FOR TREATMENT OF HYPERTRIGLYCERIDEMIC-RELATED CONDITIONS INCLUDING ACUTE PANCREATITIS
    Publication number: 20170202929
    Abstract: A lipoprotein lipase (LPL) protein for treating and/or preventing HTG and its associated diseases, including but not limited to acute pancreatitis (AP), and in particular, acute pancreatitis secondary to or exacerbated by hypertriglyceridemia, and hypertriglyceridemia and its associated diseases in general, including cardiovascular and metabolic diseases, endocrine disorders, and fat embolism syndrome.
    Type: Application
    Filed: January 20, 2017
    Publication date: July 20, 2017
    Inventors: Omar L. Francone, Lin Guey, Kevin Holmes, Bruce Tangarone, Matthew Traylor, Lenore von Krusenstiern, Tracy Dowie, Lieh Yoon Low, Bohong Zhang, Muthuraman Meiyappan, Angela Norton, Bettina Strack-Logue, Dianna Lundberg, Michael F. Concino
  • Lipoprotein lipase for treatment of hypertriglyceridemic-related conditions including acute pancreatitis
    Patent number: 9597376
    Abstract: A lipoprotein lipase (LPL) protein for treating and/or preventing HTG and its associated diseases, including but not limited to acute pancreatitis (AP), and in particular, acute pancreatitis secondary to or exacerbated by hypertriglyceridemia, and hypertriglyceridemia and its associated diseases in general, including cardiovascular and metabolic diseases, endocrine disorders, and fat embolism syndrome.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: March 21, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Omar L. Francone, Lin Guey, Kevin Holmes, Bruce Tangarone, Matthew Traylor, Lenore von Krusenstiern, Tracy Dowie, Lieh Yoon Low, Bohong Zhang, Muthuraman Meiyappan, Angela Norton, Bettina Strack-Logue, Dianna Lundberg, Michael F. Concino
  • LIPOPROTEIN LIPASE FOR TREATMENT OF HYPERTRIGLYCERIDEMIC-RELATED CONDITIONS INCLUDING ACUTE PANCREATITIS
    Publication number: 20160051637
    Abstract: A lipoprotein lipase (LPL) protein for treating and/or preventing HTG and its associated diseases, including but not limited to acute pancreatitis (AP), and in particular, acute pancreatitis secondary to or exacerbated by hypertriglyceridemia, and hypertriglyceridemia and its associated diseases in general, including cardiovascular and metabolic diseases, endocrine disorders, and fat embolism syndrome.
    Type: Application
    Filed: August 19, 2015
    Publication date: February 25, 2016
    Inventors: Omar L. Francone, Lin Guey, Kevin Holmes, Bruce Tangarone, Matthew Traylor, Lenore von Krusenstiern, Tracy Dowie, Lieh Yoon Low, Bohong Zhang, Muthuraman Meiyappan, Angela Norton, Bettina Strack-Logue, Dianna Lundberg, Michael F. Concino
  • Disruption of the prostaglandin E synthase 2 gene
    Publication number: 20030106085
    Abstract: The present invention features genetically-modified non-human mammals and animal cells containing a disrupted prostaglandin E synthase 2 gene as well as methods of treating an inflammation-mediated disorder involving administering an agent that inhibits prostaglandin E synthase 2.
    Type: Application
    Filed: November 13, 2002
    Publication date: June 5, 2003
    Applicant: Pfizer Inc.
    Inventors: Laurent P. Audoly, Omar L. Francone, Mehrdad Haghpassand, John E. Hambor, Marsha L. Roach, Jeffrey L. Stock
  • Assay for ABCA1
    Patent number: 6555323
    Abstract: This invention relates to novel methods of measuring the activity and/or levels of ABCA1 protein, including the use of acceptors of ABCA1 substrates, as well as methods involving the measurement of ABCA1 mRNA and protein levels.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: April 29, 2003
    Assignee: Pfizer Inc.
    Inventors: Mark J. Bamberger, Omar L. Francone
  • Assay for ABCA1
    Publication number: 20020061511
    Abstract: This invention relates to novel methods of measuring the activity and/or levels of ABCA1 protein, including the use of acceptors of ABCA1 substrates, as well as methods involving the measurement of ABCA1 mRNA and protein levels.
    Type: Application
    Filed: January 17, 2001
    Publication date: May 23, 2002
    Inventors: Mark J. Bamberger, Omar L. Francone